PURPOSE OF REVIEW: To review evidence on the validity and utility of recent approaches to subtyping late-life mild cognitive impairment. RECENT FINDINGS: There is growing evidence that amnestic mild cognitive impairment is associated with biomarkers for Alzheimer's disease, while nonamnestic mild cognitive impairment maps more closely to cerebrovascular disease. The former is more likely to progress to dementia than the latter. Mild impairment in multiple cognitive domains appears to represent a more advanced disease state than single-domain impairment, and is more likely to progress to dementia. The cognitive subtypes have imprecise boundaries and have limited ecological validity. Approaches to subtyping that also incorporate biomarkers increase diagnostic specificity and have greater predictive value. However, these approaches have yet to be validated outside specialized memory clinic populations. SUMMARY: Mild cognitive impairment as currently defined is still etiologically and prognostically heterogeneous, particularly outside specialty clinical settings. The objective of further subtyping is to delineate subgroups that are more clinically homogeneous. The current cognitive subtypes have some validity and utility but additional approaches should be explored so as to enhance these properties.
PURPOSE OF REVIEW: To review evidence on the validity and utility of recent approaches to subtyping late-life mildcognitive impairment. RECENT FINDINGS: There is growing evidence that amnestic mild cognitive impairment is associated with biomarkers for Alzheimer's disease, while nonamnestic mild cognitive impairment maps more closely to cerebrovascular disease. The former is more likely to progress to dementia than the latter. Mild impairment in multiple cognitive domains appears to represent a more advanced disease state than single-domain impairment, and is more likely to progress to dementia. The cognitive subtypes have imprecise boundaries and have limited ecological validity. Approaches to subtyping that also incorporate biomarkers increase diagnostic specificity and have greater predictive value. However, these approaches have yet to be validated outside specialized memory clinic populations. SUMMARY:Mildcognitive impairment as currently defined is still etiologically and prognostically heterogeneous, particularly outside specialty clinical settings. The objective of further subtyping is to delineate subgroups that are more clinically homogeneous. The current cognitive subtypes have some validity and utility but additional approaches should be explored so as to enhance these properties.
Authors: Mary Ganguli; Beth E Snitz; Judith A Saxton; Chung-Chou H Chang; Ching-Wen Lee; Joni Vander Bilt; Tiffany F Hughes; David A Loewenstein; Frederick W Unverzagt; Ronald C Petersen Journal: Arch Neurol Date: 2011-06
Authors: P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl Journal: Neurology Date: 2007-01-23 Impact factor: 9.910
Authors: B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen Journal: J Intern Med Date: 2004-09 Impact factor: 8.989
Authors: E Mariani; R Monastero; S Ercolani; F Mangialasche; M Caputo; F T Feliziani; D F Vitale; U Senin; P Mecocci Journal: Dement Geriatr Cogn Disord Date: 2007-11-01 Impact factor: 2.959
Authors: Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe Journal: Brain Date: 2007-10-10 Impact factor: 13.501
Authors: Vladimir Hachinski; Costantino Iadecola; Ron C Petersen; Monique M Breteler; David L Nyenhuis; Sandra E Black; William J Powers; Charles DeCarli; Jose G Merino; Raj N Kalaria; Harry V Vinters; David M Holtzman; Gary A Rosenberg; Anders Wallin; Martin Dichgans; John R Marler; Gabrielle G Leblanc Journal: Stroke Date: 2006-08-17 Impact factor: 7.914
Authors: Perminder S Sachdev; Deborah Blacker; Dan G Blazer; Mary Ganguli; Dilip V Jeste; Jane S Paulsen; Ronald C Petersen Journal: Nat Rev Neurol Date: 2014-09-30 Impact factor: 42.937
Authors: David R Roalf; Madelyn J Moberg; Bruce I Turetsky; Laura Brennan; Sushila Kabadi; David A Wolk; Paul J Moberg Journal: J Neurol Neurosurg Psychiatry Date: 2016-12-30 Impact factor: 10.154
Authors: Erin L Abner; Richard J Kryscio; Gregory E Cooper; David W Fardo; Gregory A Jicha; Marta S Mendiondo; Peter T Nelson; Charles D Smith; Linda J Van Eldik; Lijie Wan; Frederick A Schmitt Journal: Int J Alzheimers Dis Date: 2012-03-25